The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
UNITY BIOTECHNOLOGY, INC. | COM | 91381U200 | 3,970 | 10,048,181 | SH | SOLE | 0 | 0 | 10,048,181 | ||
DENALI THERAPEUTICS, INC. | COM | 24823R105 | 112,594 | 3,668,749 | SH | SOLE | 0 | 0 | 3,668,749 | ||
METACRINE, INC. | COM | 59101E103 | 1,426 | 2,940,503 | SH | SOLE | 0 | 0 | 2,940,503 | ||
KARUNA THERAPEUTICS, INC. | COM | 48576A100 | 295,304 | 1,312,872 | SH | SOLE | 0 | 0 | 1,312,872 | ||
RUBIUS THERAPEUTICS, INC. | COM | 78116T103 | 152 | 349,908 | SH | SOLE | 0 | 0 | 349,908 | ||
SINGULAR GENOMICS SYSTEMS, INC. | COM | 82933R100 | 9,497 | 3,798,926 | SH | SOLE | 0 | 0 | 3,798,926 | ||
EQRX, INC. | COM | 26886C107 | 179,860 | 36,335,375 | SH | SOLE | 0 | 0 | 36,335,375 | ||
ERASCA, INC. | COM | 29479A108 | 86,233 | 11,055,554 | SH | SOLE | 0 | 0 | 11,055,554 | ||
VERVE THERAPEUTICS, INC. | COM | 92539P101 | 69,003 | 2,008,809 | SH | SOLE | 0 | 0 | 2,008,809 | ||
REVOLUTION HEALTHCARE ACQUISITION CORP. | COM | 76155Y108 | 13,342 | 1,357,237 | SH | SOLE | 0 | 0 | 1,357,237 |